Observing how upadacitinib works for Crohn's disease in Japan
Part of Digestive system clinical trials.
This study is for people with moderate to severe Crohn's disease who are starting a medication called upadacitinib. Researchers will watch how the disease changes over time and check for any side effects. It's an observational study, meaning you'll keep getting your regular treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with moderate to severe Crohn's disease.
- Your doctor has prescribed upadacitinib (a medication) for your Crohn's disease.
- You are starting upadacitinib within the next 14 days or have already started it within that time.
- You are not taking part in any other clinical research study.
- You do not have any medical reason that prevents you from taking upadacitinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
This trial tests combining two medicines, vedolizumab and upadacitinib, to see if they work better together than vedolizumab alone for people with moderate to severe Crohn's disease that hasn't responded well to other treatments.
This study looks at how adults with Crohn's disease or ulcerative colitis are doing after taking upadacitinib (Rinvoq) for at least 12 months. It helps doctors understand treatment patterns and outcomes in real-world settings.
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.